Eli Lilly
U.S. pharma major behind Mounjaro and Zepbound — the biggest beneficiary of the obesity-drug boom.
Coverage of Eli Lilly is fading : 3 signals on the latest tracked day, down 57% from its three-week baseline of 7, across 3 domains (unchanged from a week ago). That makes it the #345 most-covered of the 349 concerns we track.
If Eli Lilly matters to your work, attention is draining away — the pace of news no longer demands a daily check.
What’s changed
- Amplia Therapeutics Partners with Eli Lilly in FAK-KRAS Combination Lung Cancer Trial - smallcaps.com.au · KRAS Mutation Research (Google News) · 2026-08-04
- Lilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of previously treated KRAS G12C-mutant advanced pancreatic cancer - Eli Lilly and Company · KRAS Mutation Research (Google News) · 2026-08-03
- Danish politicians call out Eli Lilly obesity campaign · Fierce Pharma · 2026-08-18 · usually covers FDA Decisions
- STAT+: Eli Lilly targets booming black market for retatrutide · STAT News — All Content · 2026-08-14 · usually covers Biotech Pharma
- Pursuing patient options, Novo kicks off trial testing smaller doses of Wegovy pill · Fierce Pharma · 2026-08-21 · usually covers FDA Decisions
- Oncology Company Expands Footprint At Hines' Life Sciences Campus · Bisnow · 2026-08-21 · usually covers Commercial Real Estate
What the reporting says
Across 49 tracked stories from 25 outlets, reporting on Eli Lilly most often describes regulatory approvals (13), public statements (2).
It shows up alongside KRAS (10), FDA (15), Merck (11), Bristol Myers Squibb (9), Novo Nordisk (9), Astrazeneca (8), GLP-1 (8).
Two steps out: AI (through FDA, 15 shared stories on the weaker link); Cder (through FDA, 15 shared stories on the weaker link); Colorectal Cancer (through FDA, 15 shared stories on the weaker link); Drug Administration (through FDA, 15 shared stories on the weaker link).
Tracked since May 6, with coverage on 20 separate days — concentrated in Kras Research.